Syndax Pharmaceuticals (SNDX) Interest & Investment Income (2015 - 2026)

Syndax Pharmaceuticals' Interest & Investment Income history runs 12 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 50.42% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $19.1 million (down 26.56% YoY), while the FY2025 annual figure was $22.7 million, down 12.88% from the prior year.
• Interest & Investment Income was $3.6 million for Q1 2026 at Syndax Pharmaceuticals, down from $4.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $7.3 million in Q1 2024 to a low of $224000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $4.7 million across 5 years, with a median of $5.3 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Interest & Investment Income soared 3183.52% in 2022, then plunged 50.42% in 2026.
• A 5-year view of Interest & Investment Income shows it stood at $3.0 million in 2022, then jumped by 85.74% to $5.6 million in 2023, then gained by 28.07% to $7.1 million in 2024, then tumbled by 39.11% to $4.3 million in 2025, then retreated by 17.72% to $3.6 million in 2026.
• The last three Interest & Investment Income figures came in at $3.6 million (Q1 2026), $4.3 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.